Get the free sample of high bioactivity ADC targets
ADCs (Antibody-drug conjugates) are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens with highly potent anti-cancer agents linked via a chemical linker, while sparing normal cells from damage, potentially minimizing the side effects associated with cancer therapy. Since the approval of the first ADCs in 2000, there are now nine different approved ADCs on the market and over 100 ADCs in the drug-development pipeline.
List of ADCs have been approved
We believe that with the development hotspot of ADCs from hematomas to solid tumors, choosing the suitable drug target proteins will become more and more important.
ACROBiosystems has developed a series of products with different species and tags for a variety of hot targets, which are suitable for immune, antibody screening, SPR, cell activity detection and other experiments. ACROBiosystems is committed to assisting you in drug development, and all SPR&BLI protocols are available for free. In addition, over expressed cell lines and kit products will be coming soon.